Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Daiichi Sankyo Company, Limited
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Competitor Comparison == The company's key competitors are Merck & Co Inc, Takeda Pharmaceutical Co Ltd., Astellas Pharma Inc, and Chugai Pharmaceutical Co Ltd., with the latter 3 companies being headquartered in Japan and the former being headquartered in the United States. Daiichi Sankyo's primary income stream comes from Japan, any revenue generated from '''T-DXds''' and '''Dato-DXds''' must be split by 50% with AstraZeneca according to their partnership agreement for sales outside of Japan (See in Products). As such, their primary competitors will be located in Japan. Daiichi Sankyo is the only company to focus heavily on breast cancer treatment in contrast to its competitors, with only Chugai Pharma equalling it in this area, with Chugai having several anti-HER2 monoclonal antibodies, competing with Daiichi Sankyo's T-DXd drugs (ENHERTU). However, Daiichi Sankyo heavily outcompetes Chugai in terms of revenue made from oncology drugs, with Daiichi Sankyo's oncology revenue at >900 Bn JPY as of 2023 and Chugai's at 256 Bn JPY as of 2022. The Japanese competitors, although they do focus on oncology development, all focus on different cancers and cancer types. This is due to competition within the oncology sector being inherently minimal as a result of the vast array of potential drug targets, frequently leading to collaboration as opposed to competition.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)